Press Releases

Home/Press Releases

Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA

1,125 patients combined in both studies Efficacy data available after the 6-month dosing NEW YORK, Oct. 16, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the [...]

2020-10-16T08:40:00+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

Oral Presentation on Oral Insulin Effect on Diabetes and Poster Presentation on Oral Insulin Effect on NASH NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, [...]

2020-09-21T08:25:00+00:00Categories: Press Releases|Tags: |

Oramed’s Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

91% of T1D patients and 85% of T2D patients surveyed indicated they were "extremely likely" or "very likely" to ask their doctors about ORMD-0801 NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on [...]

2020-09-15T08:25:00+00:00Categories: Press Releases|Tags: |

Oramed to Present at H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global [...]

2020-09-03T08:10:00+00:00Categories: Press Releases|Tags: |

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

Data Presented at the American Diabetes Association Scientific Session 2020 NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its [...]

2020-06-15T08:25:00+00:00Categories: Press Releases|Tags: |

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

Three Poster Presentations Granted to Discuss Oral Insulin Candidate ORMD-0801 NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th [...]

2020-05-05T07:55:00+00:00Categories: Press Releases|Tags: |

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

NEW YORK, April 7, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Patent Office has indicated its intent to grant the Company a patent [...]

2020-04-07T07:40:00+00:00Categories: Press Releases|Tags: |